Suppr超能文献

慢性肠系膜缺血的经皮治疗:干预后的结果

Percutaneous management of chronic mesenteric ischemia: outcomes after intervention.

作者信息

Landis Mark S, Rajan Dheeraj K, Simons Martin E, Hayeems Eran B, Kachura John R, Sniderman Kenneth W

机构信息

School of Medicine, Department of Medical Imaging, Toronto General Hospital, University Health Network - University of Toronto, Toronto, Ontario, Canada.

出版信息

J Vasc Interv Radiol. 2005 Oct;16(10):1319-25. doi: 10.1097/01.RVI.0000171697.09811.0E.

Abstract

PURPOSE

To assess the efficacy and durability of percutaneous transluminal angioplasty (PTA)/stent placement for treatment of chronic mesenteric ischemia (CMI).

MATERIALS AND METHODS

A retrospective review of patients treated from January 1986 to August 2003 was conducted. Twenty-nine patients (mean age, 62 years) were treated for clinical symptoms consistent with CMI. Clinical diagnosis was verified with angiographic assessment and PTA with or without stent placement was performed based on angiographic and/or pressure gradient findings. Outcomes were estimated with the Kaplan-Meier method.

RESULTS

A total of 63 interventions were performed in 29 patients during the study period. Of these 63 interventions, 46 PTA and 17 stent implantation procedures were performed. Thirty-four interventions were performed for SMA stenosis/occlusion, 17 interventions for celiac artery stenosis/occlusion, and four interventions were performed on aorto-mesenteric graft stenoses. Technical success was 97%, and clinical success (defined as clinical resolution of symptoms) was 90% (26 of 29 patients). Mean duration of follow-up was 28.3 months. Primary patency for all interventions at 3, 6, and 12 months was 82.7% (95% CI: 68.7-96.7), 78.9% (66.7-91.1), and 70.1% (55.1-85.6), respectively. Primary assisted patency for all interventions at 3, 6, and 12 months was 87.9% (79.0-95.3), 87.9% (79.2-95.1), and 87.9% (77.3-98.3), respectively. An average of 1.9 interventions per patient was required. One major complication occurred (3.4%). There were three minor complications (10.3%).

CONCLUSIONS

Percutaneous intervention for CMI is safe with durable early and midterm clinical success. However, repeated intervention is often required for improved primary assisted patency.

摘要

目的

评估经皮腔内血管成形术(PTA)/支架置入术治疗慢性肠系膜缺血(CMI)的疗效和持久性。

材料与方法

对1986年1月至2003年8月期间接受治疗的患者进行回顾性研究。29例患者(平均年龄62岁)因符合CMI的临床症状接受治疗。临床诊断通过血管造影评估进行验证,并根据血管造影和/或压力梯度结果进行有或无支架置入的PTA。采用Kaplan-Meier方法评估结果。

结果

在研究期间,29例患者共进行了63次干预。在这63次干预中,进行了46次PTA和17次支架植入手术。34次干预针对肠系膜上动脉狭窄/闭塞,17次干预针对腹腔动脉狭窄/闭塞,4次干预针对主动脉-肠系膜移植血管狭窄。技术成功率为97%,临床成功率(定义为症状的临床缓解)为90%(29例患者中的26例)。平均随访时间为28.3个月。所有干预在3个月、6个月和12个月时的原发性通畅率分别为82.7%(95%CI:68.7-96.7)、78.9%(66.7-91.1)和70.1%(55.1-85.6)。所有干预在3个月、6个月和12个月时的原发性辅助通畅率分别为87.9%(79.0-95.3)、87.9%(79.2-95.1)和87.9%(77.3-98.3)。每位患者平均需要1.9次干预。发生1例严重并发症(3.4%)。有3例轻微并发症(10.3%)。

结论

CMI的经皮介入治疗安全,早期和中期临床疗效持久。然而,为提高原发性辅助通畅率,通常需要重复干预。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验